UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment considerations for patients with chronic myeloid leukemia.

Lloyd Damon, MD, discusses novel therapies in acute myeloid leukemia, including FLT3 and IDH1/2 inhibitors.

Thomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.

Bita Fakhri, MD, MPH, shares her insight on the treatment of patients with newly diagnosed multiple myeloma.

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment duration in HER2-positive breast cancer.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the management of rectal cancer.

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.

Eric A. Collisson, MD, discusses ongoing efforts to advance precision medicine in GI malignancies to improve the standard of care.

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

John Gordan, MD, PhD, discusses the challenges of treating patients with biliary tract cancers and novel therapies in development.

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma.

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the interest in the pegylated hyaluronidase agent, PEGPH20, and clinical trials exploring other emerging agents in pancreatic cancer.

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.

Andrew Ko, MD, professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses exciting data from the 2018 Gastrointestinal Cancers Symposium.

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).

Eric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the focus of clinical trial research and genetic testing in gastrointestinal (GI) cancers.

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses de-escalation in HER2-positive breast cancer.

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with multiple myeloma.

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.